

ASX Announcement

21 October 2026

Update on Commercial Terms for the Proposed Merger with Microba Life Sciences

- Genetic Signatures Limited (ASX: GSS) (GSS) and Microba Life Sciences Limited (ASX: MAP) (Microba) have agreed, in principle, to revised terms for the proposed merger, under which Microba shareholders would hold 60% of GSS on implementation (previously ~67%) and existing GSS shareholders would hold 40% (previously ~33%).
- All other material terms of the proposed merger remain unchanged and an addendum to the Notice of AGM (which includes an additional resolution to approve the proposed merger) is currently with ASX and is expected to be released shortly. The addendum will include a summary of the key terms of the proposed merger as well as other relevant information.

Genetic Signatures Limited (ASX: GSS) (GSS or the Company) refers to its announcement of 22 September 2026 in relation to the commercial terms of the proposed merger of GSS and Microba Life Sciences Limited (ASX: MAP) (**Microba**) (**Proposed Merger**). Under the Proposed Merger, GSS would acquire all of the issued securities in Microba by way of concurrent Court-approved share and option schemes of arrangement (together, the **Proposed Scheme**).

Amendment to the exchange ratio

The principal change under the amended terms relates to the agreed exchange ratio. Under the revised terms, Microba shareholders will hold 60% of the total GSS shares on issue upon implementation (previously approximately 67%), while existing GSS shareholders will hold 40%. The final number of GSS shares to be issued will be determined under the scheme formula by reference to the number of GSS and Microba shares on issue at the scheme record date.

The scheme formula that will be used for the purpose of calculating the number of shares and options to be received by holders of Microba shares or options is as follows:

$$N = \frac{0.6 \times \left(\frac{A}{0.4}\right)}{B}$$

Where:

N is the number of GSS shares or GSS options to be issued for each Microba share or Microba option held as at the scheme record date, respectively;

A is the total number of GSS Shares on issue as at the scheme record date; and

B is the total number of Microba Shares on issue at the scheme record date.

Accordingly, the placement announced by Microba earlier today will not be dilutive to GSS shareholders by operation of the scheme formula.

GSS and Microba are yet to enter into binding documentation and the transaction terms remain subject to ongoing due diligence. The revised terms will be recorded in the scheme implementation deed (**SID**), the material terms of which will be summarised in an addendum to the Company's Notice of Annual General Meeting (**Addendum**). The Addendum is currently with ASX for review and is subject to ASX approval prior to its release.

Transaction otherwise unchanged and progressing

Other than the proposed amendment to the scheme formula described above, the material terms of the Proposed Merger, including the strategic rationale for the transaction, remain unchanged. The GSS Board continues to unanimously recommend that GSS shareholders vote in favour of the resolution to approve the issue of securities under the Proposed Merger at the Company's Annual General Meeting on 16 November 2026.

Subject to GSS shareholders approving the issue of securities under the Proposed Merger, GSS and Microba expect to execute the SID following receipt of such approval. The Proposed Merger remains subject to, among other things, approval by both GSS shareholders and Microba shareholders and option holders and the Court.

This announcement has been authorised for release by both the Board of Genetic Signatures Limited and Microba Life Sciences Limited.

– END –

For further information contact:

Mike Aicher
Chair
Genetic Signatures
info@geneticsignatures.com

Pasquale Rombola
Chair
Microba Life Sciences
investor@microba.com

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

About Microba Life Sciences

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba – Expect better. www.microba.com

Forward looking statements

This announcement may contain certain 'forward-looking statements' about the financial condition, results of operations and business of GSS, and certain plans and objectives of the Board and management of genetic signatures, including in relation to the proposed merger. Forward looking statements can generally be identified by words such as 'may', 'could', 'believes', 'plan', 'will', 'likely', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These risks and uncertainties may include, but are not limited to, the outcome and effects of the subject matter of this announcement, including whether the proposed merger will be implemented on the revised terms or at all, its timing, the number of GSS securities to be issued, the ownership structure of GSS on implementation, and the timing and content of the Addendum. You are cautioned not to place undue reliance on forward looking statements, as actual outcomes may differ materially from them.

Any forward-looking statements, opinions and estimates provided in this announcement necessarily involve uncertainties, assumptions, contingencies and other factors, and unknown risks may arise, many of which are outside the control of GSS and Microba. The actual results, achievement or performance of GSS, Microba, or of the combined group, may be materially different from any future results, achievement or performance expressed or implied by such forward looking statements. Forward-looking statements, including without limitation guidance on future plans, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Such forward looking statements speak only as of the date of this announcement. To the maximum extent permitted by law, each of GSS and Microba disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise.